CN106248921A8 - 利用透明质酸评价肾损伤的方法和组合物 - Google Patents

利用透明质酸评价肾损伤的方法和组合物 Download PDF

Info

Publication number
CN106248921A8
CN106248921A8 CN201610569328.4A CN201610569328A CN106248921A8 CN 106248921 A8 CN106248921 A8 CN 106248921A8 CN 201610569328 A CN201610569328 A CN 201610569328A CN 106248921 A8 CN106248921 A8 CN 106248921A8
Authority
CN
China
Prior art keywords
kidney
injury
composition
evaluated
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610569328.4A
Other languages
English (en)
Other versions
CN106248921A (zh
Inventor
J·安德伯格
J·格雷
P·麦克弗森
K·中村
J·P·坎普夫
K·辛巴提
J·A·小凯勒姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Astute Medical Inc
Original Assignee
University of Pittsburgh
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh, Astute Medical Inc filed Critical University of Pittsburgh
Publication of CN106248921A publication Critical patent/CN106248921A/zh
Publication of CN106248921A8 publication Critical patent/CN106248921A8/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

本发明涉及对罹患或疑患有肾损伤的受试者进行监测、诊断、预后和确定治疗方案的方法和组合物。具体地说，本发明涉及采用检测一种或多种透明质酸(HA)的测定在肾损伤中作为诊断和预后生物标记物测定。
CN201610569328.4A 2010-09-24 2011-09-23 利用透明质酸评价肾损伤的方法和组合物 Pending CN106248921A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38642110P 2010-09-24 2010-09-24
US61/386,421 2010-09-24
CN201180047897.8A CN103189394B (zh) 2010-09-24 2011-09-23 利用透明质酸评价肾损伤的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180047897.8A Division CN103189394B (zh) 2010-09-24 2011-09-23 利用透明质酸评价肾损伤的方法和组合物

Publications (2)

Publication Number Publication Date
CN106248921A CN106248921A (zh) 2016-12-21
CN106248921A8 true CN106248921A8 (zh) 2017-07-21

Family

ID=45874188

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180047897.8A Active CN103189394B (zh) 2010-09-24 2011-09-23 利用透明质酸评价肾损伤的方法和组合物
CN201610569328.4A Pending CN106248921A (zh) 2010-09-24 2011-09-23 利用透明质酸评价肾损伤的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201180047897.8A Active CN103189394B (zh) 2010-09-24 2011-09-23 利用透明质酸评价肾损伤的方法和组合物

Country Status (13)

Country Link
US (1) US20130252264A1 (zh)
EP (1) EP2619231B1 (zh)
JP (1) JP2013541005A (zh)
KR (1) KR20140051099A (zh)
CN (2) CN103189394B (zh)
AU (1) AU2011305197B2 (zh)
BR (1) BR112013006631A2 (zh)
CA (1) CA2813011A1 (zh)
EA (1) EA201390294A1 (zh)
ES (1) ES2619617T3 (zh)
MX (1) MX348303B (zh)
NZ (1) NZ609126A (zh)
WO (1) WO2012040592A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150241415A1 (en) * 2012-08-11 2015-08-27 Astute Medical, Inc. Evaluating renal injury using hyaluronic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
ES2150915T3 (es) 1991-04-12 2000-12-16 Biosite Diagnostics Inc Nuevos conjugados y dosificados destinados para la deteccion simultanea de ligandos multiples.
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP2004208693A (ja) * 2002-12-17 2004-07-29 Sanyo Chem Ind Ltd 抗ヒアルロン酸抗体、これを含む試薬キット、抗ヒアルロン酸抗体の製造法及びヒアルロン酸の測定法
US20070259380A1 (en) * 2004-05-20 2007-11-08 Kyoichi Sumida Method for Measuring Hyaluronic Acid Using Hyaluronic Acid Binding Protein
WO2009140026A2 (en) * 2008-04-18 2009-11-19 Pharmacophotonics, Llc D/B/A Fast Diagnostics Renal function analysis method and apparatus
US20090298106A1 (en) * 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8673574B2 (en) * 2008-08-21 2014-03-18 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
CN102187220B (zh) * 2008-08-28 2015-08-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US8501489B2 (en) * 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
CN106546752A (zh) * 2009-02-06 2017-03-29 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
CN104698161A (zh) * 2009-12-20 2015-06-10 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物

Also Published As

Publication number Publication date
WO2012040592A1 (en) 2012-03-29
AU2011305197A1 (en) 2013-05-02
NZ609126A (en) 2015-05-29
MX2013003204A (es) 2013-06-05
JP2013541005A (ja) 2013-11-07
KR20140051099A (ko) 2014-04-30
CN106248921A (zh) 2016-12-21
BR112013006631A2 (pt) 2017-10-24
EP2619231A1 (en) 2013-07-31
AU2011305197B2 (en) 2015-06-11
EP2619231A4 (en) 2014-04-30
CN103189394B (zh) 2016-08-17
EP2619231B1 (en) 2016-12-21
ES2619617T3 (es) 2017-06-26
US20130252264A1 (en) 2013-09-26
CN103189394A (zh) 2013-07-03
CA2813011A1 (en) 2012-03-29
MX348303B (es) 2017-06-06
EA201390294A1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
EP3070474A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
WO2012012693A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2014201516A3 (en) Biomarker identification
WO2010041046A3 (en) Granin proteins as markers of heart disease
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
WO2012174282A3 (en) Biomarker compositions and methods
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2012110878A3 (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014004889A3 (en) Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
WO2012006056A3 (en) Ccr6 as a biomarker of alzheimer's disease
WO2010075360A3 (en) Methods for detection of sepsis
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2010046648A3 (en) Diagnostic test for streptococcus equi
MX2014000283A (es) Metodos y composiciones para diagnóstico y pronóstico de lesión e insuficiencia renal.
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2013011294A3 (en) Diagnosis of alzheimer's disease
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Inventor

Correct: Anderberg Joseph|Gray Jeff|Mcpherson Paul|Nakamura Kevin|Kampf James Patrick|Singbartl Kai|Kellum John A. Jr.

False: Anderberg Joseph|Gray Jeff|Mcpherson Paul|Nakamura Kevin|Singbartl Kai|Xin Bati|Kellum John A. Jr.

Number: 51

Volume: 32

CI02 Correction of invention patent application

Correction item: Inventor

Correct: Anderberg Joseph|Gray Jeff|Mcpherson Paul|Nakamura Kevin|Kampf James Patrick|Singbartl Kai|Kellum John A. Jr.

False: Anderberg Joseph|Gray Jeff|Mcpherson Paul|Nakamura Kevin|Singbartl Kai|Xin Bati|Kellum John A. Jr.

Number: 51

Page: The title page

Volume: 32

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232598

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161221

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1232598

Country of ref document: HK